<DOC>
	<DOC>NCT02192619</DOC>
	<brief_summary>The registry aims to document epidemiologic data, treatment and long-term outcome as well as quality of life of patients with APL. Additionally, a biobanking project for further translational studies is integrated. Prospective population-based non-interventional and non-randomized multicenter registry.</brief_summary>
	<brief_title>National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup</brief_title>
	<detailed_description>- collection of epidemiological data for APL: age distribution, prognostic factors, distribution of subgroups, incidence - documentation of efficacy and safety of the first line and salvage therapy in APL including - documentation of minimal residual disease (MRD) - correlation of clinical outcomes with chosen therapy - collection and evaluation of quality of life - validation of published prognostic factors / new potential prognostic factors - acquisition of bone marrow, peripheral blood and buccal swab samples for biobanking and translational studies under the umbrella of the specific study-group biobanking concepts</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
	<criteria>newlydiagnosed APL (either de novo or therapyrelated), within 12 months of diagnosis or relapsed APL, within 12 months of diagnosis of relapse 1. confirmed by the presence of the translocation t(15; 17) 2. and / or confirmed by the detection of the fusion transcript of PML/RARa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>APL</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>AML M3</keyword>
</DOC>